DURAVYU shows promise in Phase 2 trial for eye disease
WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...
News Medical13h
High HDL cholesterol may increase glaucoma risk in older adults
Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Managed Healthcare Executive19h
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
Researchers probe potential role of Ozempic, other weight-loss drugs in vision loss
Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...